Ehave (EHVVF) Bullish Outlook on Recession and Growing Mental Health Crisis

(NEW YORK)–Ludlow Research initiates research opinion on Ehave, Inc. (OTC: EHVVF), a leading healthcare services and technology company, based on growing risk for mental health crisis and demand for alternative treatment options.

BULLISH OUTLOOK IN RECESSION

Ehave is a healthcare technology company, which is focused on healthcare data collection, management, and analytics for the mental health and wellness market.

Their core mission is to create safe and effective therapeutics that will help achieve better patient outcomes when dealing with brain health issues such as depression, anxiety, and PTSD.

As economies across the globe emerge from pandemic restrictions many nations are facing a growing mental health crisis resulting from economic stress and long waiting lines for psychiatric care.

Increases in mental health disorders, such as anxiety, depression, and post-traumatic stress disorder (PTSD) are resulting in renewed demand for alternative mental health treatments, which could result in higher consumer demand for Ehave services into 2023.

This business model could position Ehave operations as sort of a hedge to any economic recession.

For these reasons, Ludlow Research has initiated coverage on Ehave, Inc. (OTC:EHVVF) with a ‘speculative’ valuation target of $0.04 per share, or $14 million market valuation.

To download report please visit https://ludlowresearch.com/reports/

HEALTHCARE DATA MANAGEMENT

MetaHealthU platform is a powerful mobile application that empowers individuals to take complete control of their health and their healthcare data. MetaHealthU allows users to securely track all their health data from wearables, Electronic Health Records Systems (EHRs), doctors, and medical labs.

Healthcare data management is the process of storing, protecting, and analyzing data pulled from diverse sources. Managing the wealth of available healthcare data allows health systems to create holistic views of patients, personalize treatments, improve communication, and enhance health outcomes.

BLOCKCHAIN IN HEALTHCARE

MetaHealthU is developing platfrom to utilize Web3 blockchain technology for healthcare data management and secure data storage.

Integrating Web3 in healthcare can give the power over data back to users and help handle a structured data management system. The data stored in Web3 is distributed, personalized and traceable, eventually bringing transparency, accessibility and affordability to the healthcare ecosystem.

To receive investor updates on this report register at
https://ludlowresearch.com/investors/

About Ehave, Inc.

Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave’s operations span across the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company’s website at: www.ehave.com

---

Disclosures and Disclaimer:

THE MATERIAL HEREIN DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION WHERE OR TO ANY PERSON TO WHOM IT WOULD BE UNAUTHORIZED OR UNLAWFUL TO DO SO.

This reports contains certain statements that may be deemed “forward-looking” statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Ludlow Research (“Ludlow”), and its parent company Ludlow Consulting, LLC, are not registered broker-dealers or investment advisers with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”), or any state securities regulatory authority.

Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. Ludlow, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encouraged to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Ludlow was compensated three thousand six hundred dollars for research report, and holds business relationships through affiliate company, and thus should be considered a conflict of interest when reviewing this information. Investments is speculative ‘penny stocks’, as defined by the SEC, may involve a high degree of risk.

INVESTORS ARE HIGHLY ENCOURAGED TO CONSULT WITH A FINANCIAL ADVISOR BEFORE MAKING ANY AND ALL INVESTMENT DECISIONS.